Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19)

Background and objectives: COVID-19 patients exhibit a broad range of manifestations, presenting with a flu-like respiratory tract infection that can advance to a systemic and severe disease characterized by pneumonia, pulmonary edema, severe damage to the airways, and acute respiratory distress syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Ullah, Sami, Abid, Radhya, Haider, Sana, Khuda, Fazli, Albadrani, Ghadeer M., Abdulhakim, Jawaher A., Altyar, Ahmed E., Abdel-Daim, Mohamed M., Halimi, Syed Muhammad Ashhad, Khalil, Atif Ali Khan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412443/
https://www.ncbi.nlm.nih.gov/pubmed/36013543
http://dx.doi.org/10.3390/medicina58081076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412443/
https://www.ncbi.nlm.nih.gov/pubmed/36013543
http://dx.doi.org/10.3390/medicina58081076

Ejemplares similares